High rates of failure, exorbitant costs, and the sluggish pace of new drug discovery and
development have led to a growing interest in repurposing “old” drugs to treat both common …

Cancer is among the leading causes of death worldwide and it is estimated that in 2040
more than 29 million people will be diagnosed with some type of cancer. The most prevalent …

Cancer, a complex and multifactorial disease, presents a significant challenge to global
health. Despite significant advances in surgical, radiotherapeutic and immunological …

Simple Summary Cancer mortalities are growing at an alarming pace around the globe, a
fact related to challenges, such as side effects, selectivity, and resistance, accompanied by …

Simple Summary Novel pharmacological approaches are needed to improve treatments of
advanced cancers, despite the considerable benefit of immunotherapy. New drugs are …

Chemotherapy is an effortless and frequently used approach in cancer therapy. However, in
most cases, it can only prolong life expectancy and does not guarantee a complete cure …

Pirfenidone, an antifibrotic drug, has antitumor potential against different types of cancers.
Our work explored whether pirfenidone sensitizes non-small cell lung cancer (NSCLC) cell …

Ibrutinib has potential therapeutic or protective effects against viral-and bacterial-induced
acute lung injury (ALI), likely by modulating the Bruton tyrosine kinase (BTK) signaling …

The rationale for using thalidomide (THD) as a treatment for nausea and vomiting during
pregnancy in the late 1950s appears to have been based on its sedative or hypnotic …

PCL-based nanoparticles for doxorubicin-ezetimibe co-delivery: A combination therapy for
prostate cancer using a drug repurposing strategy - PMC Back to Top Skip to main content NIH …